VBI Vaccines (NASDAQ:VBIV) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.
Earnings and Valuation
This table compares VBI Vaccines and Atreca’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VBI Vaccines||$3.36 million||31.30||-$63.60 million||($0.97)||-0.61|
Insider & Institutional Ownership
26.6% of VBI Vaccines shares are owned by institutional investors. Comparatively, 56.5% of Atreca shares are owned by institutional investors. 10.5% of VBI Vaccines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for VBI Vaccines and Atreca, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
VBI Vaccines currently has a consensus price target of $4.33, suggesting a potential upside of 634.46%. Atreca has a consensus price target of $24.41, suggesting a potential upside of 126.41%. Given VBI Vaccines’ higher possible upside, equities research analysts clearly believe VBI Vaccines is more favorable than Atreca.
This table compares VBI Vaccines and Atreca’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Atreca beats VBI Vaccines on 5 of the 8 factors compared between the two stocks.
About VBI Vaccines
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.